Search results for: 'ma8a fuels develop deceleration'

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

This research service encompasses microbiome technology trends and emerging innovations across: Disease Management This research segment explores the emerging role of microbiome-based therapeutics across a wide range of diseases, especially in the context of gastro-intestinal health, while providing strategic insights across the highly dynamic com...

10 May 2023  |  Global  |  Market Research

Growth Opportunities in the Biologics Contract Development and Manufacturing Organization Sector

Value Chain Expansion to Support Next generation Biologics Drives Future Growth Potential

Infographics

×

This research service provides an overview of the global biologics contract development and manufacturing organization (bio-CDMO) market and a 6-year market revenue forecast (2023 to 2028). The geographic scope covers three key regions, namely North America (NA); Europe; and Asia-Pacific (APAC). The report offers a detailed segment analysis of...

The Frost & Sullivan research service discusses the cell and gene therapy (CGT) market and highlights some key roadblocks in viral vector manufacturing. While many CGT candidates exist in the pipeline, there is a huge capacity deficit that the industry is collaboratively trying to address. Scalability, costs, reproducibility, and overall process ef...

As the global population ages, more attention should be paid to the needs of individuals aged 45 to 55, particularly women in the perimenopausal and menopausal stages. Women aged 45 and above are at a crucial stage in terms of professional and personal responsibilities; however, they are challenged by menopausal symptoms, such as hot flashes, sleep...

The impressive advances in life sciences research and development (R&D) befallen in the past two-three years are playing a leading role in the transformation of the healthcare industry. A myriad of new developments in the fields of gene and cell therapies, empowered with nanotechnology advances, omics technologies and novel smart molecules approach...

This research service investigates technologies that propel the development of new targeted immunotherapies, particularly those that deliver therapeutic DNA and proteins. The top 3 growth opportunities focus on enhanced gene delivery systems for greater precision, the support of such systems through novel biotech platforms, and the affordability of...

29 Aug 2022  |  Global  |  Technology Research

Advancements in miRNA: Technology Assessment

Developments in miRNA sequencing and analysis are driving future growth potential in therapeutics and diagnostics

Infographics

×

Accelerated research around RNA-based therapeutics and diagnostics, accompanied by technology advancements in sequencing the human genome, has resulted in a better understanding of the role of miRNA in biological pathways, enhancing its potential in both therapeutics and diagnostics. The successful clinical validation of miRNA diagnostic tests has ...

09 Nov 2022  |  Global  |  Technology Research

Emerging Therapeutics for Rare Neuromuscular Diseases: Pipeline Analysis

Strategic partnering and new product development will enable better biologics for personalized and targeted treatment

Infographics

×

Muscle weakness, cramps, and impaired musculoskeletal functions that occur due to rare defects in nerve and muscle cells characterize neuromuscular disorders (NMDs). The disorders are largely classified as motor neuron diseases, hereditary ataxias, peripheral nerve disorders, neuromuscular junction transmission disorders, and myopathies. NMDs prese...